The loss of the Yushatan storm is serious, can Huahai Pharmaceuticals get out of the difficult situation in 2019?

Huahai Pharmaceuticals currently business to specialty raw materials and preparations mainly, raw materials mainly include antihypertensive, psychotic and anti-AIDS and other characteristics of raw materials, and
company is the world's largest supplier of puli, shatan drugs;Huahai Pharmaceuticals is the world's leading supplier of primies and sartans. Huahai Pharmaceuticals, which suffered from the haze of the "Yushatan incident", on April 30, disclosed its 2018 financial results: full-year operating income of
was RMB5,094 million, while net profit attributable to shareholders of listed companies decreased by 81.05 percent from a year earlier, the lowest level in nearly six years. At the same time, the company announced in its earnings report that it was ending its tradition of continuing dividends since it went public in 2003.to mention the loss of more than 400 million yuan Huahai Pharmaceuticals' current business to characteristics of raw materials and preparations, raw materials mainly include antihypertensive, psychotic and anti-AIDS and other specialty raw materials, and the company is also
is the world's largest supplier of primli, sartan drugs;The "Yusatan incident" refers to last July, the European Medicines Agency (EMA) issued a notice that Huahai Pharmaceuticals production of the raw materials of pyrethroids was detected a carcinogen called N-MDMAMINE (NDMA) impurities, the EMA decided to carry out an evaluation investigation of the API. The company's share price fell and its market value took a hit after it was banned by the US and European Drug Administration at the end of September.Financial results revealed that in addition to business pressure, the Fushatan incident also led to a substantial increase in additional losses and expenses of Huahai Pharmaceutical Industry, the Fushatan incident caused by the recall losses, inventory impairment
losses, compensation losses, etc. based on the actual occurrence of the cumulative loss of about 413 million yuan.Among them, sales of RAW drugs and intermediates decreased by 6.23% YoY, mainly due to the recall of API salatin and the impact of the EU ban on some products, and sales expenses increased to RMB1,294 million from RMB905 million a year earlier, an increase year-on-year 43.0%, partly due to increased market maintenance and "crisis management" costs to reduce the impact of the Sandtan incident, and an increase of 2,420.11% in out-of-business expenses over the same period last year, mainly due to customer compensation estimated for the products affected by the FDA ban.Sun Corporation abandoned its plan to list in the United States
announced that due to the impact of the occasional incident of luscosa impurities, by the board of directors of Sun's Prosun Biopharmaceutical Co., Ltd. on October 8, 2018 passed, Prosun Biopharmaceutical Co., Ltd. abandoned the U.S. listing plan, while buying back a minority shareholder's 24.24 percent stake in Prosun Biopharmaceutical Co., Ltd., the end of the purchase price payable.Financial report also mentioned that after the incident, Huahai Pharmaceuticals suspended the production and sale of related products, actively recall related products, with national regulatory authorities
inspection and rectification, and with customers, consumers and other communication and consultation. The company has received 15 lawsuits from U.S. consumers.The company has now completed the recall of domestic salatan API, the recall of foreign raw materials is progressing in an orderly manner
, most of which have been recalled;2019, can we get out of this mess?Although Huahai Pharmaceuticals' 2018 API and preparation exports were greatly affected by the Saats incident, sales of finished products increased by 9.26% YoY, and of the 25 varieties selected for the first batch of 4-7 volume purchases in December last year, Huahai Pharmaceuticals won six products, temporarily gaining the advantage of the number of varieties. Huahai Pharmaceuticals disclosed in its 2018 financial results that its 2019 business plan targets "to achieve sales revenue of 5.4 billion yuan."Huahai Pharmaceuticals also said that it will take the purchase of volume as an opportunity to seize the window period brought about by consistent evaluation, timely adjust the marketing model, adhere to the grade hospitals and primary hospitals and
development, and focus on the advantages of the market outside the 4-7 city.Q1 quarterly report, released on the same day, showed that the company's first-quarter operating income of 1,199 million yuan, net profit of 136 million yuan. Don't forget the teacher of the past. Willing to experience a storm in the international market Huahai Pharmaceutical Industry, through the new growth engine, more and more smooth. (Medical Rubik's Cube)